

In the Claims:

Please cancel claims 12-14 and 22-29 without prejudice.

Please amend claims 1, 4-7, 16, 17 and 21 as follows:

B2
1. (Amended) Isolated Apo-2DcR polypeptide having at least about 80% amino acid sequence identity with native sequence Apo-2DcR polypeptide comprising amino acid residues 1 to 259 of [Fig. 1A (JSEQ ID NO: 1)].

B3
4. (Amended) Isolated native sequence Apo-2DcR polypeptide comprising amino acid residues 1 to 259 of [Fig. 1A (JSEQ ID NO:1)].

5. (Amended) Isolated extracellular domain sequence of Apo-2DcR polypeptide comprising amino acid residues 1 to 161 of [Fig. 1A (JSEQ ID NO:1)].

6. (Amended) The extracellular domain sequence of claim 5 comprising amino acid residues 1 to 236 of [Fig. 1A (JSEQ ID NO:1)].

7. (Amended) Isolated native sequence Apo-2DcR polypeptide comprising amino acid residues [-40] 1 to [259] 299 of [Fig. 1B (JSEQ ID NO:3)].

B4
16. (Amended) The nucleic acid of claim 15 wherein said nucleic acid encodes native sequence Apo-2DcR polypeptide comprising amino acid residues 1 to 259 of [Fig. 1A (JSEQ ID NO:1)].

17. (Amended) The nucleic acid of claim 15 comprising nucleotides 193 to 969 of [Fig. 1A (JSEQ ID NO:2)].

B5
21. (Amended) A process of using a nucleic acid molecule encoding Apo-2DcR polypeptide to effect production of Apo-2DcR polypeptide comprising culturing the host cell of claim 20 under conditions such that the Apo-2DcR polypeptide is produced.